G1 Therapeutics Inc (GTHX) Expected to Announce Earnings of -$0.72 Per Share
Brokerages forecast that G1 Therapeutics Inc (NASDAQ:GTHX) will post ($0.72) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.85) and the highest estimate coming in at ($0.66). G1 Therapeutics reported earnings of ($0.64) per share during the same quarter last year, which would suggest a negative year over year growth rate of 12.5%. The business is expected to announce its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that G1 Therapeutics will report full-year earnings of ($2.91) per share for the current fiscal year, with EPS estimates ranging from ($3.14) to ($2.67). For the next year, analysts expect that the business will report earnings of ($3.70) per share, with EPS estimates ranging from ($4.60) to ($3.23). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05.
A number of large investors have recently added to or reduced their stakes in GTHX. Federated Investors Inc. PA lifted its stake in G1 Therapeutics by 98.3% during the first quarter. Federated Investors Inc. PA now owns 2,039 shares of the company’s stock worth $34,000 after purchasing an additional 1,011 shares in the last quarter. Legal & General Group Plc increased its position in shares of G1 Therapeutics by 20.0% during the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after acquiring an additional 676 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of G1 Therapeutics by 1,539.2% during the first quarter. BNP Paribas Arbitrage SA now owns 5,098 shares of the company’s stock worth $85,000 after acquiring an additional 4,787 shares during the period. Meeder Asset Management Inc. increased its position in shares of G1 Therapeutics by 147.7% during the fourth quarter. Meeder Asset Management Inc. now owns 4,484 shares of the company’s stock worth $87,000 after acquiring an additional 2,674 shares during the period. Finally, NumerixS Investment Technologies Inc purchased a new stake in shares of G1 Therapeutics during the first quarter worth $98,000. Institutional investors own 73.47% of the company’s stock.
NASDAQ:GTHX traded down $0.45 during trading hours on Thursday, reaching $23.32. 273,500 shares of the stock were exchanged, compared to its average volume of 335,481. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $69.57. The stock has a market capitalization of $890.59 million, a price-to-earnings ratio of -9.11 and a beta of 2.50.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Featured Story: Dollar Cost Averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.